Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Definitive Agreement with DaVita Clinical Research and Site Location and Principal Investigator of Hepatitis C Virus (HCV) Clinical Study

SAN DIEGO - May 20, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has entered into a definitive agreement with DaVita Clinical Research (DCR) to provide clinical management services to support the forthcoming feasibility study of the Aethlon Hemopurifier®. The Hemopurifier is a first-in-class therapeutic device that targets the rapid elimination of circulating viruses and tumor-secreted exosomes that suppress the immune system of cancer patients. Aethlon further announced that the Principal Investigator for this study will be Dr. Stephen Z. Fadem.

The clinical trial site location will be DaVita MedCenter Dialysis in Houston. Dr. Fadem is co-medical director of DaVita MedCenter Dialysis and this center is one of the three largest dialysis centers in the country with 72 treatment stations.
Aethlon previously disclosed that the United States Food and Drug Administration (FDA) had approved an Investigational Device Exemption (IDE) that allows the Company to initiate human feasibility studies of the Aethlon Hemopurifier in the United States. Under the feasibility study protocol, Aethlon is to treat ten ESRD patients infected with Hepatitis C virus (HCV) to demonstrate the safety of Hemopurifier therapy. Successful completion of the feasibility study will set the stage for Aethlon to conduct pivotal studies required for market clearance to treat HCV and potentially other disease indications.
"The combination of DCR, DaVita MedCenter Dialysis, and Dr. Fadem provides Aethlon with the ideal team of professionals and infrastructure with which to conduct our infectious disease clinical study. Additionally, their proximity to M.D. Anderson Cancer Center and other specialty facilities located within the Texas Medical Center provide for a unique location to conduct future clinical investigations of Hemopurifier® therapy in a variety of life-threatening health conditions," stated Aethlon Medical CEO Jim Joyce.
DCR is a specialty contract research organization (CRO) with experience in conducting more than 300 early phase clinical trials. As a subsidiary of DaVita Healthcare Partners Inc, DCR has access to one third of the total U.S. ESRD patient population and maintains a network that exceeds 150 investigative physicians' practices at more than 250 clinical sites.
Dr. Fadem is a practicing Houston nephrologist and is currently the Chief Medical Officer at Kidney Associates, PLLC and the Medical Director for the Houston Kidney Center Integrated Service Network at DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. He began practice in 1978 after completing a renal fellowship at The University of Texas Health Science Center in San Antonio. He is a graduate of the University of Oklahoma College of Medicine, and did his internal medicine residency at The University of Texas and MD Anderson Hospital in Houston. He is a Clinical Professor of Medicine at Baylor College of Medicine.
He is a Fellow of the American College of Physicians, Fellow of the American Society of Nephrology, diplomat of the American Board of Quality Assurance and Utilization Review Physicians (CHCQM - Certified Health Care Quality Management), and a member of the International Society of Nephrology, Renal Physicians Association, the American Association of Kidney Patients and The National Kidney Foundation. He is active in quality management, credentialing and peer review for his dialysis centers.
On a national level, he is co-chairman of the Medical Advisory Board of the American Association of Kidney Patients, and a past vice-president of the Board of Directors. He has also served on the Board of Directors of the Renal Physicians Association, and actively serves on two national RPA committees, the Government Affairs Committee and the Health Finance Committee. Dr. Fadem has been active in the Forum of ESRD (end stage renal disease) Networks and was a member of the CMS Clinical Performance Measures Committee. He lectures frequently on dialysis management, preventive nephrology, vascular calcification, anemia, patient education, CKD education, computer technology and computer security. Dr. Fadem is a co-editor of AAKP Renalife and is a reviewer for several peer reviewed journals.
Dr. Fadem has been nationally recognized by receiving the American Association of Kidney Patient's Nova Award, the National Kidney Foundation's Distinguished Service Award. He has also received the National Kidney Foundation's Presidents Award and the Myron L. Jenkins Award. He has been awarded the Peter Lundin Award for his contributions to patient education and The Visionary Award for his contributions to CKD education. He is the 2013 winner of the DaVita Core Value Award for Continuous Improvement. He has been named as one of America's Top Doctors by Castle Connolly and US News and World Report, and is consistently ranked as a Top Doctor in Houston by Texas Magazine.
About DaVita Kidney Care
DaVita Kidney Care is a division of DaVita HealthCare Partners Inc., a Fortune 500® company that, through its operating divisions, provides a variety of health care services to patient populations throughout the United States and abroad. A leading provider of dialysis services in the United States, DaVita Kidney Care treats patients with chronic kidney failure and end stage renal disease. DaVita Kidney Care strives to improve patients' quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of March 31, 2014, DaVita Kidney Care operated or provided administrative services at 2,098 outpatient dialysis centers located in the United States serving approximately 165,000 patients. The company also operated 75 outpatient dialysis centers located in 10 countries outside the United States. DaVita Kidney Care supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company's leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu. For more information, please visit DaVita.com.
About Aethlon Medical, Inc.
Aethlon Medical creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients. The lead Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as well as tumorsecreted exosomes that suppress the immune system of cancer patients. Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression. Additional information can be found at www.AethlonMedical.com
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's existing or future clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: 2425 quarterly for annual news publishing only starting Feb 26th 2014
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar

See the CNBC Ad for NXT-ID's (OTCQB:NXTD) Next Generation Smart Wallet, Wocket™, Now on Youtube.com

SHELTON, CT - May 16, 2014 (Investorideas.com Newswire) NXT-ID, Inc. (OTCQB: NXTD) a biometric authentication company focused on the growing m-commerce market, is pleased to release to consumers and shareholders the first series of 30 second spots on CNBC for its next generation smart wallet, Wocket™.

The commercial is available to view on the company home page at http://www.nxt-id.com/ and on youtube.com at http://www.youtube.com/watch?v=8kJid_JAbhg
Wocket™ is a smart wallet in the same vein as the smart phone and smart watch. NXT-ID is introducing its innovative, patent-pending Wocket™ as the next natural step in the evolution of smart devices. Wocket™ is a next generation smart wallet designed to replace all the cards in your wallet, with no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval.
Credit, debit, ATM, loyalty, gift, ID, membership, insurance, ticket, emergency, medical, business, contacts, coupon, and virtually any card can be protected on Wocket™. More than 10,000 cards, records, coupons, etc. and 100 voice commands can also be stored on Wocket™.
The consumer get to know Wocket™ campaign is in advance of the previously announced May 28 th press conference and marketing event to be held at the Plaza Hotel in New York City.
Media and shareholders wishing to attend the May 28 th event can email info@nxt-id.com
Advance orders will be available following the May 28 th event at 5:00 PM EST at http://www.wocketwallet.com/
Wocket Consumer FAQ:

"What is Wocket ™?

Wocket™ is a smart wallet. Like the smart phone and smart watch, NXT-ID is introducing its innovative, patent-pending Wocket™ as the next natural step in the evolution of smart devices.
"What does Wocket™ do?
Wocket™ locks all of your private information in an electronic "vault", where only an authenticated owner can authorize access to the data. Thus, you can "lock it with Wocket™ in your pocket", protecting your private information from unauthorized access.
"What makes Wocket™ smart?
Wocket™ smart wallet protects all of your private information inside an electronic vault while reducing the number of cards in your wallet. Dynamic pairing for authentication and encrypted data transfer with other secondary devices along with a plethora of new, innovative features makes Wocket™ the smartest wallet ever devised.
"How is Wocket™ different from other smart card solutions?
Wocket™ is not a smart card - it is a smart wallet. Thus, it can communicate with smart cards, but is not limited in the number, type, or method of communication of private information that typically restricts the use of a smart card. Furthermore, Wocket™ is not dependent on proximity or any other external factors to secure and choose soft-cards containing private information.
"How is Wocket™ different from other digital wallet solutions?
Rather than replace a wallet as many "digital wallet" technologies attempt to do, we chose to improve the wallet. Unlike other digital wallet solutions that depend on connectivity to choose a payment account, Wocket™ does not depend upon the cloud to select or make a payment.
"Does Wocket™ require another device, such as a cell phone?
No. Although Wocket™ does not require any other peripheral for security or "proximity sensing", Wocket™ can authenticate with secondary devices prior to transaction as an additional step in security as well as utilize a Wocket™ app on other devices to select or manage a soft-card, all without revealing private information.
"How do I access my private information?
A combination of biometrics, personal PIN or pattern provides multi-factor security for your Wocket™. Once Wocket™ verifies your identity, you can simply select whatever soft-card or information you want from the touch screen display, or in some configurations, your voice command.
"How many cards can be securely stored on a Wocket™?
Up to 10,000 cards, records, coupons, etc. and up to 100 voice commands can also be stored on Wocket™. More can be supported with optional additional memory.
The full Wocket product FAQ is available to consumers and media at
http://nxt-id.com/wocket-faq/
Advance orders will be available following the May 28 th event at 5:00 PM EST at http://www.wocketwallet.com/

About NXT- ID Inc. -Mobile Security for a Mobile World
NXT-ID, Inc.'s (OTCQB: NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms led by the Wocket™ ; a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval. http://www.thewocket.com/, http://www.wocketwallet.com/
NXT-ID’ wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/
Forward-Looking Statements for NXT-ID
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.
Contact:
Corporate info: info@nxt-id.com
Investor Inquiries:
Kirin Smith
ProActive Capital Group
Direct: 646 863 6519
ksmith@proactivecapital.com
Media: 800 665-0411

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: November 2013: Investorideas is compensated by NXTD: five thousand per month for news publication and syndication and is long 144 shares from previous service. More info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Mining Stock Alert: SilverCrest (TSX: SVL) (NYSE MKT: SVLC) Reports Q1 2014 Financial Results

Vancouver, British Columbia - May 15, 2014 (Investorideas.com Mining Stocks Newswire) SilverCrest Mines Inc. (TSX:SVL) ( NYSE MKT: SVLC) is pleased to announce its financial results for the first quarter ended March 31, 2014. All financial information is prepared in accordance with IFRS and all dollar amounts are expressed in U.S. dollars unless otherwise specified. The information in this news release should be read in conjunction with the Company's unaudited condensed consolidated interim financial statements for the three months ended March 31, 2014 and associated management discussion and analysis ("MD&A") which are available from the Company's website at www.silvercrestmines.com and under the Company's profile on SEDAR at www.sedar.com.

N. Eric Fier, President and COO stated, "We are pleased with the steady start to 2014, for which operating costs and production were consistent with budget, although our financial performance compared to the first quarter of 2013 was impacted by lower metal prices. Our all-in sustaining cash costs per silver equivalent ounce sold (2) at $9.71 continues to makes us one of the lowest cost precious metal producers. With the commissioning of our new 3,000 tpd mill, SilverCrest is well positioned to continue to generate strong operating cash flows in H2 2014, with continued strengthening of its cash position of $54.5 million at March 31, 2014."
FINANCIAL HIGHLIGHTS OF Q1, 2014, Compared to Q1, 2013:

• Cash flow from operations (1) decreased 25% to $6.6 million ($0.06 per share).
• Cash operating cost per silver equivalent ounce sold (2) decreased 7% to $7.14.
• All-in sustaining cash cost per silver equivalent ounce sold (2) decreased 40% to $9.71.
• Revenues reported decreased 15% to $13.0 million.
• Metal sales of 198,800 ounces of silver and 7,650 ounces of gold increased 27% and 4% respectively.
• Realized spot metal prices declined from $30 to $21 (30%) for silver and from $1,626 to $1,319 (19%) for gold.
• Net earnings were $2.5 million ($0.02 per share), compared to $6.0 million ($0.06 per share).
• Cash and cash equivalents were $54.5 million (at March 31, 2014), compared to $41.1 million (at March 31, 2013).
• Working capital was $63.7 million (at March 31, 2014), compared to $48.9 million (at March 31, 2013).
• Bullion inventory at March 31, 2014, included 59,114 ounces of silver and 2,084 ounces of gold.

Comparison of the three months ended March 31, 2014 to March 31, 2013
Net earnings were $2,467,989 ($0.02 per share basic) for the first quarter compared with $6,002,276 ($0.06 per share basic) in 2013. The decrease in net earnings during the first quarter was primarily attributed by lower revenues resulting from significantly lower realized prices.
Silver and gold revenue totalled $13,005,527 (2013 - $15,329,642) in the first quarter. Silver sales totalled 198,800 ounces (2013 - 157,088), 27% higher than the same period in 2013. The foregoing, combined with a 30% lower average realized price at $21 (2013 - $30) per ounce, resulted in 12% less silver revenue. Total gold revenue reported in the first quarter decreased 16% compared to the same period in 2013. Total gold sales were 7,650 ounces (2013 - 7,370) or 4% above 2013. The Company sold 6,120 (2013 - 5,896) ounces of gold at an average realized price of $1,319 (2013 - $1,626) per ounce, a 19% decline and delivered 1,530 gold ounces (2013 - 1,474) under the Sandstorm Purchase Agreement at $350 per ounce.
Cost of sales amounted to $4,686,523 (2013 - $4,368,519). Operating cash cost per silver equivalent ounce sold amounted to $7.14, Ag:Au 60.0:1 (2013 - $7.69, Ag:Au 55.8:1). The decrease in operating cash cost per silver equivalent ounce sold is driven generally by the difference in silver equivalence ratios. The 40% decrease in all-in sustaining cash costs from Q1 2013, is primarily due to lower exploration costs incurred by the Company during Q1 2014.
General and administrative expenses increased by 10% to $1,477,002 (2013 - $1,340,926) primarily due to an increase in regulatory expenses resulting from the onetime TSX listing fee.
(1) Cash flow from operations before changes in working capital items.
(2) These are Non-IFRS performance measures. Refer to "CAUTIONARY NOTE REGARDING NON-IFRS PERFORMANCE MEASURES". Silver equivalent ("AgEq") ounces consist of the number of ounces of silver production/sold plus the number of ounces of gold production/sold multiplied by a 60:1 gold price to silver price ratio. Prior to Q1 2014, the AgEq ratio was based on the spot gold price to the spot silver price at the quarter end dates for financial reporting. All numbers are rounded.
OUTLOOK
SilverCrest's immediate focus is to (i) continue its efficient operation of its flagship Santa Elena low cost silver and gold mine, (ii) complete commissioning of the new 3,000 tonne per day CCD-MC processing plant, (iii) complete accelerated development of the underground mine for initial underground production, (iv) expand resources and subsequent reserves at Santa Elena by systematic exploration of the deposit, (v) evaluate and acquire exploration properties in proximity to Santa Elena, (vi) complete evaluation of certain aspects at the La Joya Project to a Pre-Feasibility Study level in 2014.
CONFERENCE CALL
A conference call to discuss the results will be held on Thursday, May 15th. The call will be held at 10am PDT (1pm EDT). To participate in the conference call, please dial the following:
Participant Dial In Number(s)
Local / International: 416-849-5572
North American Toll-Free: 1-866-809-6768
A replay of the conference call will be archived for later playback on the Company's website at www.silvercrestmines.com.
SilverCrest Mines Inc. (NYSE MKT: SVLC; TSX: SVL) is a Canadian precious metals producer headquartered in Vancouver, BC. SilverCrest’s flagship property is the 100%-owned Santa Elena Mine, located 150 km northeast of Hermosillo, near Banamichi in the State of Sonora, México. The mine is a high-grade, epithermal silver and gold producer, with an estimated life of mine of 8 years and operating cash costs of $11 per ounce of silver equivalent (55:1 Ag:Au) for the open pit heap leach and underground mine. SilverCrest anticipates that the new 3,000 tonnes per day conventional mill facility at the Santa Elena Mine should recover an average annual rate of 1.5 million ounces of silver and 32,800 ounces of gold over the current reserve. Major expansion and construction of the 3,000 tonnes per day conventional mill facility is nearing completion and is expected to significantly increase metals production at the Santa Elena Mine (open pit and underground) in 2014 and beyond. Exploration programs continue to make new discoveries at Santa Elena and also have rapidly advanced the definition of a large polymetallic deposit at the La Joya property in Durango State, Mexico.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking statements" within the meaning of Canadian securities legislation and the United States Securities Litigation Reform Act of 1995. Such forward-looking statements concern the Company's anticipated results and developments in the Company's operations in future periods, planned exploration and development of its properties, plans related to its business and other matters that may occur in the future. These statements relate to analyses and other information that are based on expectations of future performance, including silver and gold production and planned work programs. Statements concerning reserves and mineral resource estimates may also constitute forward-looking statements to the extent that they involve estimates of the mineralization that will be encountered if the property is developed and, in the case of mineral reserves, such statements reflect the conclusion based on certain assumptions that the mineral deposit can be economically exploited.
Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements, including, without limitation: risks related to precious and base metal price fluctuations; risks related to fluctuations in the currency markets (particularly the Mexican peso, Canadian dollar and United States dollar); risks related to the inherently dangerous activity of mining, including conditions or events beyond our control, and operating or technical difficulties in mineral exploration, development and mining activities; uncertainty in the Company's ability to raise financing and fund the exploration and development of its mineral properties; uncertainty as to actual capital costs, operating costs, production and economic returns, and uncertainty that development activities will result in profitable mining operations; risks related to reserves and mineral resource figures being estimates based on interpretations and assumptions which may result in less mineral production under actual conditions than is currently estimated and to diminishing quantities or grades of mineral reserves as properties are mined; risks related to governmental regulations and obtaining necessary licenses and permits; risks related to the business being subject to environmental laws and regulations which may increase costs of doing business and restrict our operations; risks related to mineral properties being subject to prior unregistered agreements, transfers, or claims and other defects in title; risks relating to inadequate insurance or inability to obtain insurance; risks related to potential litigation; risks related to the global economy; risks related to the Company's status as a foreign private issuer in the United States; risks related to all of the Company's properties being located in Mexico and El Salvador, including political, economic, social and regulatory instability; and risks related to officers and directors becoming associated with other natural resource companies which may give rise to conflicts of interests. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in the forward-looking statements. The Company's forward-looking statements are based on beliefs, expectations and opinions of management on the date the statements are made. For the reasons set forth above, investors should not place undue reliance on forward-looking statements.
N. Eric Fier, President & COO
SILVERCREST MINES INC.
Neither TSX Exchange nor its Regulation Services Provider (as defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact:
Fred Cooper
Telephone: (604) 694-1730 ext. 108
Toll Free: 1-866-691-1730
Email: info@silvercrestmines.com
Website: www.silvercrestmines.com
Address: Suite 501 - 570 Granville Street
Vancouver, BC Canada V6C 3P1
Published at Investorideas.com Newswire
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: SilverCrest Mines has compensated Investorideas.com for the distribution and publishing of this news release (annual news publication 9700) http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

TSX News Alert: Garibaldi (TSXV: GGI) drills bonanza grade silver near-surface at Silver Eagle target, Rodadero

VANCOUVER - May 14, 2014 (Investorideas.com Mining stocks newswire) Garibaldi Resources Corp. (GGI.V) (the "Company" or "Garibaldi") is pleased to report that it has intersected exceptionally high silver grades within 30 meters of surface in first-ever drilling at the Company's 45 sq. km Rodadero North Project in central Sonora State, Mexico . A second drill hole has started.

Highlights:

• First hole at Silver Eagle target (SE-14-01) returned 2,010 g/t Ag (65 oz/ton) over 7 meters (23.1 feet) including 3 meters (9.9 feet) grading 4,565 g/t Ag (147 oz/ton);
• A 50-meter step-out hole to the south of SE-14-01 has commenced;
• Garibaldi's exploration team has identified 7 high-priority targets in addition to Silver Eagle at Rodadero North - data compilation and regional work continues.

Steve Regoci , Garibaldi President and CEO, commented: "We're excited with these initial drill results at Rodadero where we have made very effective use of hyperspectral remote sensing technology to outline a broad area of prospective targets. Given these numbers from Rodadero, and our recent solid drill results at La Patilla, we are moving at an accelerated pace in Mexico . In northwest British Columbia , we are extremely encouraged by the near-term discovery potential of our flagship Grizzly Project that covers more than half of the Sheslay Cu-Au porphyry district mineralized corridor. Garibaldi is uniquely positioned in two friendly jurisdictions to build shareholder value."
Silver Eagle Target, Rodadero North
The first hole at Silver Eagle, drilled with Garibaldi's company-owned rig, was designed to follow up on surface sampling along a silicified zone. DDH SE-14-01 intersected a strongly mineralized 7-meter zone.
Significant assay results, DDH SE-14-01:
At the present time, the geometry of the mineralized system is not known and true width for the drill intercepts remains to be determined. The widths given are downhole core lengths. The cut-off for the 7-meter intercept is 20 g/t Ag. The hole was drilled to a length of 100 meters.
The Silver Eagle target is an apparently flat lying silicified body that alters the upper parts of a conglomerate unit that overlies andesitic volcanic rocks. The silicified body is cut by several silver-bearing fractured zones that may reflect feeders to the silicified 'cap'.
"We eagerly anticipate results from this next hole at Silver Eagle," added Regoci. "In Mexico we're also preparing for follow-up drilling at La Patilla and initial drilling at Iris. We have low exploration and drilling costs in Mexico , and these are also partly offset by continued royalty income from our pilot coal program at the Tonichi Project."
Rodadero North & Rodadero South Target Areas
The Rodadero region hosts multiple precious metal occurrences over several tens of kilometers. Garibaldi has identified seven other targets at Rodadero North - Rambo, La Guata, Batuc , La Fortuna , La Colorada , Tarichi and Igualama - through mapping, sampling and the use of the Company's proprietary hyperspectral database. To date, two targets have also been outlined at Rodadero South, where less exploration has been carried out, approximately five kilometers southeast of Rodadero North. A map showing the two project areas and targets is attached with this release and will be posted at www.GaribaldiResources.com in the Mexico "Projects" section under "Rodadero". Alamos Gold's Mulatos mine and Agnico Eagle's La India mine are approximately 90 kilometers to the southeast.
Live Webinar and Corporate Video
Garibaldi will be conducting a live investor Webinar Wednesday, May 21 , beginning at 1:15 p.m. Pacific (4:15 pm Eastern) through MarketSmart Communications Inc., official investor relations for Garibaldi. Log-in instructions for this presentation can be found on the Garibaldi homepage (www.GaribaldiResources.com).
Garibaldi is also pleased to announce the release of an updated short corporate presentation (video). You can view the video by going to the following web site URL: http://www.garibaldiresources.com/s/Media.asp#video
Quality Assurance & Control
Garibaldi maintains strict QA-QC protocols for all aspects of its exploration programs that include the systematic insertion of blanks and standards into each sample batch. Acme Labs (now part of the Bureau Veritis group that includes BSI Inspectorate) performed assay analyses on core reported in this release, and ALS Global (formerly ALS Chemex) performed analyses on rock samples. All samples were assayed using certified and industry standard assay techniques for gold and multi-element packages and for over-limits. Au was analyzed by 30 or 50 gram fire assay with an atomic absorption finish, and other elements were analyzed by multi-element ICP. Samples in excess of 1,500 g/t Ag were analyzed by gravimetric methods.
Qualified Person
Dr. Craig Gibson , Certified Professional Geologist and a director of Garibaldi, is a non-arms length Qualified Person for the Company's Mexico projects and the direct manager of the technical programs operated under contract by Prospeccion Y Desorrollo Minera del Norte (ProDeMin). Dr. Gibson has reviewed this news release and approved the content thereof.
About Garibaldi
Garibaldi Resources Corp. is an active Canadian-based junior exploration company focused on creating shareholder value through discoveries and strategic development of its assets in some of the most prolific mining regions in Mexico and British Columbia.
We seek safe harbor.
GARIBALDI RESOURCES CORP.
Per: "Steve Regoci"
Steve Regoci , President
Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or the accuracy of this release.
SOURCE Garibaldi Resources Corp.
Image with caption: "Garibaldi drills bonanza grade silver near-surface at Silver Eagle target, Rodadero (CNW Group/Garibaldi Resources Corp.)". Image available at: http://photos.newswire.ca/images/download/20140514_C8286_PHOTO_EN_40292.jpg
Contact:
GARIBALDI RESOURCES CORP.
1150 - 409 Granville Street
Vancouver, BC V6C 1T2
Telephone: (604) 488-8851
Website: www.GaribaldiResources.com
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocksDescription: http://images.intellitxt.com/ast/adTypes/icon1.png or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. InvestorIdeas has been paid 75.00 for dissemination of this press release. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) CEO Note: Cancer Treatment Discovery, Exosomes Transport Pharmaceutical Industry Targets

SAN DIEGO - May 14, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce

The discovery that our Hemopurifer® captures tumor-secreted exosomes provides hope for a new therapeutic paradigm to augment cancer care. Yes, the same Hemopurifier® we are preparing to advance in a forthcoming FDA approved infectious disease study. In my last CEO note, I referenced a National Institute of Health (NIH) – National Cancer Institute (NCI) sponsored article that referenced Hemopurifier® therapy as a candidate to address tumor-secreted exosomes.
The article detailed several exosomal mechanisms that promote cancer progression, including suppression of the immune system, triggering resistance to cancer therapies, promotion of angiogenesis and seeding the spread of metastasis. The article also indicated that high levels of circulating exosomes correlated with advanced stage cancer.
As researchers continue to unravel the deleterious mechanisms of exosomes underlying cancer, it has become clear that these particles also transport many molecular targets of interest to the pharmaceutical industry. Thus providing further support for a medical device that is able to target circulating exosomes without adding drug toxicity to established cancer therapies.
In this regard, I am pleased to share the following overview authored by Dr. Annette Marleau (our Director of Tumor Immunology), which outlines oncology targets of the pharmaceutical industry that have been reported to be transported by exosomes.
Therapeutic Elimination of Cancer Exosomes: Delivery Vehicles For A Spectrum of Pharmaceutical Industry Targets
The Aethlon Hemopurifier® is a first-in-class extracorporeal hemofiltration device with the ability to capture and retain disease-mediating particles from the entire circulatory system. Utilizing existing hemodialysis infrastructure, Hemopurifier® cartridges are packed with a carbohydrate-binding protein known as GNA, which has a unique affinity for glycosylated particles that are typically released in large quantities by diseased cells.
Among the disease targets that can be addressed by Hemopurifier® therapy are exosomes (also sometimes referred to as extracellular vesicles or microvesicles). Previously thought to represent unwanted cellular debris, an explosion of research has now proven that exosomes serve as primary transportation systems between the body's cells. In disease conditions such as cancer, pathogenic material from diseased cells is packaged into exosomes and released into circulation, thereby unleashing the cancer's arsenal of malignant signals throughout the body. In recent years, the scientific community has identified a complement of disease-causing proteins and genes carried in the exosomal cargo, the tumor's essential blueprint. Exosomes are thus major purveyors of aggressive cancer phenotypes, able to provide the comprehensive array of mediators for tumor growth and metastasis, drug resistance, immune suppression, and angiogenesis.
Drawing from the surplus of possible targets in cancer therapeutics, pharmaceutical companies are vying in a race for clinical enhancement and commercialization of a plethora of drug candidates, including tyrosine kinase inhibitors (TKI) and monoclonal antibodies (mAb) directed at specific mediators of malignancy. We envision that addressing exosomes therapeutically could serve as a strategy for dealing with many of these disease targets simultaneously. Indeed, an analysis of the drug targets being pursued by the pharmaceutical industry reveals that many of these targets are actually transported by cancer exosomes during the disease process. Included in the pipeline of promising oncology drugs are immune checkpoint inhibitors targeting programmed cell death protein 1 (also known as PD-1) and its ligand (PD-L1, B7-H1), a molecular pathway triggered by exosomes that contributes to muted anti-cancer responses. As underscored by the list that follows, the drug targets present in exosomes encompass the breadth of molecular pathways that are exploited by tumors to escape immune surveillance and hijack host tissues, including CTLA-4, HGF/met, FGF, b-Raf, EGFR, HER2, CD20, P-glycoprotein, and VEGF/VEGFR.
Immune Suppression
Programmed Cell Death 1 & Ligand (PD-1/PD-1L):

• Merck: Lambrolizumab/MK-3475 (anti-PD-1 mAb)
• Bristol-Myers Squibb: Nivolumab/BMS-936558 (anti-PD-1 mAb)
• CureTech/Teva: Pidilizumab/CT-011 (anti-PD-1 mAb)
• Roche/Genentech: MPDL3280A (anti-PD-L1 mAb)
• Medimmune/AstraZeneca: MEDI4736 (anti-PD-L1 mAb).
• Amplimmune/GlaxoSmithKline: AMP-224 (PD-L2-IgG1 Fc fusion protein).

CTLA-4

• Bristol-Myers Squibb: Ipilimumab/Yervoy® (anti-CTLA-4 mAb)
• Medimmune/Pfizer: Tremelimumab/CP-675-206 (anti-CTLA-4 mAb)

Tumor Growth & Metastasis
Hepatocyte growth factor (HGF) & Receptor (Met):

• Amgen: Rilotumumab/AMG 102 (anti-HGF mAb)
• Genentech/Roche: Onartuzumab/OA-5D (anti-Met mAb)
• Aveo: Ficlatuzumab/AV-299 (anti-HGF mAb)
• Amgen: AMG 337 (MET TKI)
• Eli Lilly: LY-2875358 (anti-Met mAb).
• ArQule: Tivantinib/ARQ 197 (MET TKI)
• Novartis/Incyte: INCB28060/INC280 (MET TKI)

Fibroblast growth factor (FGF)

• Novarits: Dovitinib/TK1285 (FGFR, VEGFR & PDGF TKI)

B-raf

• GlaxoSmithKline: Tafinlar™/Dabrafenib (B-raf kinase inhibitor)
• Genentech: Zelboraf®/Vemurafenib (B-raf kinase inhibitor)

Epidermal Growth Factor Receptor (EGFR)

• Genentech: Tarceva®/Erlotinib (EGFR TKI)
• Bristol-Myers Squibb & Eli Lilly: Cetuximab/Erbitux (anti-EGFR mAb)
• Amgen: Vectitbix/Panitumumab (anti-EGFR mAb)
• Boehringer Ingelheim: Gilotrif™/Afatinib (EGFR/HER2 TKI)

HER2

• Genentech: Herceptin®/Trastuzumab (anti-HER2 mAb)
• Genentech: Kadcyla®/Ado-trastuzumab emtansine (anti-HER2 mAb linked to DM1 drug)
• Genentech: Perjeta®/Pertuzimab (anti-HER2 mAb)
• GlaxoSmithKline: Tykerb/Lapatinib (dual TKI against HER2 and EGFR)

CD20

• Biogen Idec & Genentech: Rituxan®/Rituximab (anti-CD20 mAb)
• GlaxoSmithKline: Arzerra™/Ofatumumab (anti-CD20 mAb)
• Genentech: Gazyva™/Obinutuzumab (anti-CD20 mAb)

Drug Resistance
P-glycoprotein

• Novartis: Valspodar/PSC-833 (P-glycoprotein inhibitor).

Tumor Angiogenesis
Vascular endothelial growth factor (VEGF) & Receptor (VEGFR):

• Genentech/Roche: Avastin®/Bevacizumab (anti-VEGF mAb)
• Eli Lilly: Cyramza™ /Ramucirumab (anti-VEGFR2 mAb)
• Exelixis/GlaxoSmithKline: Foretnib/XL880/GSK1363089 (MET/VEGFR2 inhibitor).
• Sanofi & Regeneron: Zaltrap®/Ziv-Afibercept (VEGFR1/2 IgG1 Fc fusion protein)

Although this list of pharmaceutical targets and drugs is by no means all-inclusive, it highlights the broad scope of cancer's cellular pathways that can be addressed individually or in combination. While small molecule therapies are widely used against cancer, complicating factors include the development of resistance and debilitating side effects in response to these agents. Given that cancer exosomes have been reported to transport these pharmaceutical targets, therapeutic hemofiltration of exosomes offers significant clinical potential, whereby the tumor's complement of disease-mediating particles can be diminished simultaneously without additive drug toxicities or interaction risks to the patient.
About Aethlon Medical, Inc.
Aethlon Medical creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients. The lead Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as well as tumorsecreted exosomes that suppress the immune system of cancer patients. Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression. Additional information can be found at www.AethlonMedical.com
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's existing or future clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: 2425 quarterly for annual news publishing only starting Feb 26th 2014
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar

Breaking Tech News: Olivia Culpo, Former Miss Universe 2012, to Attend NXT-ID's (OTCQB: NXTD) Corporate Event for Wocket™ Smart Wallet at The Plaza Hotel on May 28th, 2014 New York City

SHELTON, CT - May 14, 2014 (Investorideas.com Newswire) NXT-ID, Inc. (OTCQB: NXTD) a biometric authentication company focused on the growing m-commerce market, announces Olivia Culpo, former Miss Universe , Miss USA and Miss Rhode Island, will be the featured celebrity guest attending the first corporate launch event and press conference for its next generation, biometrically secure smart wallet, Wocket™.

The event will take place in New York City on May 28th at the Plaza Hotel from 3:00- 5:00 p.m.
The event will give consumers and media a first-hand look at the Wocket™ Smart Wallet, the Wocket™ Card, its new logo and brand images, new consumer video and new packaging. Following the event, consumers will be able to pre-order Wocket™ online by visiting: http://www.wocketwallet.com/.
The Wocket™ has recently been featured in online media, radio and television. On Friday May 9th on Channel 3, Eyewitness News (WFSB) in CT, CEO Gino Pereira gave viewers an inside look at how the Wocket™ becomes your own personal vault for securing your identity and your payment information.
Watch the full video: http://www.wfsb.com/story/25478720/wocket-smart-wallet-stores-information-for-hundreds-of-credit-and-gift-cards
The Company also announced earlier this week that the first CNBC advertisements will air on Squawk Box, Squawk on the Street and Street Signs beginning Wednesday, May 14th, 2014. Wocket™ is a next generation smart wallet designed to protect your identity and replace all the cards in your wallet, with no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval.
The Wocket product FAQ is available to consumers and media at http://www.wocketwallet.com/
The PLAZA May 28th event is limited to one hundred attendees consisting of media and shareholders. To attend please send requests to info@nxt-id.com or call 800 665 0411.
About Olivia Culpo:
Olivia Culpo was crowned Miss Universe 2012. She was the first American representative in 15 years to win the title. Earlier that year, representing the State of Rhode Island, Culpo also won the title of Miss USA.
About NXT- ID Inc. - Mobile Security for a Mobile World
NXT-ID, Inc.'s (OTCQB: NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms led by the Wocket™ ; a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval. http://www.thewocket.com/, http://www.wocketwallet.com/
NXT-ID' wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/
Forward-Looking Statements for NXT-ID
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.
Contact:
Investor Inquiries:
Kirin Smith
ProActive Capital Group
Direct: 646 863 6519
ksmith@proactivecapital.com
Media: 800 665-0411

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: November 2013: Investorideas is compensated by NXTD: five thousand per month for news publication and syndication and is long 144 shares from previous service. More info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.